In the latest trading session, AbbVie (ABBV) closed at $216.75, marking a -2.32% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.26%. On the other hand, the Dow registered a gain of 0.6%, and the technology-centric Nasdaq increased by 0.25%.
Coming into today, shares of the drugmaker had lost 1.08% in the past month. In that same time, the Medical sector gained 0.92%, while the S&P 500 gained 1.57%.
Investors will be eagerly watching for the performance of AbbVie in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 4, 2026. The company is expected to report EPS of $3.28, up 51.85% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $16.37 billion, up 8.38% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $10.57 per share and revenue of $60.93 billion. These results would represent year-over-year changes of +4.45% and 0%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for AbbVie. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% upward. AbbVie presently features a Zacks Rank of #3 (Hold).
Looking at its valuation, AbbVie is holding a Forward P/E ratio of 15.38. This signifies no noticeable deviation in comparison to the average Forward P/E of 15.38 for its industry.
We can also see that ABBV currently has a PEG ratio of 0.91. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.61.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 216, positioning it in the bottom 12% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
